Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
Lin Zhang, Bo Hao, Zhihua Geng, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Hot and cold tumors: Immunological features and the therapeutic strategies
Lianjie Wang, Hui Geng, Yujie Liu, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 100
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial
Xiaotao Huang, Qiaodan Liu, Guihua Zhong, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 42
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study
Xiaoqing Yan, Ming Ye, Qing Zou, et al.
Annals of Oncology (2023) Vol. 35, Iss. 2, pp. 190-199
Open Access | Times Cited: 36
Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases
Zotova La
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1243-1243
Open Access | Times Cited: 33
Comprehensive Insights into Oral Squamous Cell Carcinoma: Diagnosis, Pathogenesis, and Therapeutic Advances
Dharshini Jagadeesan, Kathiresan V. Sathasivam, Neeraj Kumar Fuloria, et al.
Pathology - Research and Practice (2024) Vol. 261, pp. 155489-155489
Closed Access | Times Cited: 13
A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Cellular Therapies, and Vaccines
Dixita M. Patel, Ruba Mateen, Noor Qaddour, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 335-335
Open Access | Times Cited: 10
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 10
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial
Panpan Zhang, Si Shi, Jianming Xu, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113539-113539
Open Access | Times Cited: 9
Structure and function of therapeutic antibodies approved by the US FDA in 2023
William R. Strohl
Antibody Therapeutics (2024) Vol. 7, Iss. 2, pp. 132-156
Open Access | Times Cited: 9
Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Max Kam‐Kwan Chan, Emily Lok-Yiu Chan, Zoey Zeyuan Ji, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 316-343
Open Access | Times Cited: 19
Efficacy and safety of toripalimab with fruquintinib in the third-line treatment of refractory advanced metastatic colorectal cancer: results of a single-arm, single-center, prospective, phase II clinical study
Shoucheng Ma, Rui Chen, Ling Duan, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 2, pp. 1052-1063
Open Access | Times Cited: 17
Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
Zeynep Akbulut, Başak Aru, Furkan Aydın, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
Chunhui Zhou, Yan Li, Jiaping Li, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 15, pp. 2816-2825
Open Access | Times Cited: 15
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment
Maria Chiara Sergi, Elisabetta Filoni, Giacomo Triggiano, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 11, pp. 1247-1258
Open Access | Times Cited: 14
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
Yan Zheng, Guanghui Liang, Dongfeng Yuan, et al.
Cancer Communications (2024)
Open Access | Times Cited: 6
Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study
Chengsheng Zhang, Zhiming Zeng, Manyun Zhuo, et al.
The Oncologist (2023) Vol. 28, Iss. 12, pp. e1239-e1247
Open Access | Times Cited: 13
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, et al.
Endocrinology and Metabolism (2023) Vol. 38, Iss. 6, pp. 750-759
Open Access | Times Cited: 13
Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
Linyang Gan, Huan Chen, Xiaowei Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer
Panpan Zhang, Zhendong Chen, Si Shi, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 7
Open Access | Times Cited: 4
Development of Vogt–Koyanagi–Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report
Jia‐Ning Wang, Yue Zhang, Chen-ye Huang, et al.
BMC Ophthalmology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Toripalimab plus platinum-doublet chemotherapy as perioperative therapy for initially unresectable NSCLC: An open-label, phase 2 trial
Liang Zeng, Huan Yan, Wenjuan Jiang, et al.
Med (2025), pp. 100574-100574
Closed Access
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
Ying Cheng, Panpan Zhang, Ming Lu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool
Muhammad Nisar, Tingdong Yan, Yi Cai, et al.
Probiotics and Antimicrobial Proteins (2025)
Closed Access
Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review
Kavita Sangwan, Parveen Kumar Goyal, Vipasha Sharma
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Page 1 - Next Page

Scroll to top